Diabetic Foot Ulcer. Insulin-dependent diabetes mellitus with peripheral circulatory complications
Conditions
Interventions
Intervention 1: In the control group, placebo topical (gel containing only basis) also trained twice a day by the patient or the patient up to 28 days to five millimeters in diameter is applied on the
Placebo
Treatment - Drugs
In the control group, placebo topical (gel containing only basis) also trained twice a day by the patient or the patient up to 28 days to five millimeters in diameter is applied on the wound and final
In the intervention group Aloe vera 10% gel and Hydroalcholic extract of leave of Plantago Major (Aloe Vera 5% resin and Plantago Major 5% extract ) with trained twice a day by the patient or the pati
Sponsors
Research and Technology Vice-Chancellory of Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Type II diabetes for at least 5 years; Age between 30 to 65 years; BMI greater than 18 and less than 35; Diagnosis of neuropathic diabetic foot ulcer Wagner grade 1 or 2 Moderate infection by Internal expert; HbA1C <10; Exclusion criteria: Lack of patient follow-up; Lack of satisfaction in every stage of the study; Failure to respond to treatment; Create complications in the study conducted by treatment; Acute or severe complications of diabetes, exacerbation of underlying disease; Other systemic diseases ; Tobacco, Alcohol, Cytotoxic, Glucocorticoid, Immunosuppressive drugs; Pregnancy and lactation; Sensitivity to Aloe vera and Plantago Major plants; Diabetic foot ulcer grade 3 to 5 Wagner; Suspected osteomyelitis ( lesion size of more than 2 square centimeters )
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The area of ??the wound. Timepoint: Baseline, the end of the study. Method of measurement: Ruler and Imaging.;Deep wounds. Timepoint: Baseline, the end of the study. Method of measurement: A sterile swab.;Wound symptoms. Timepoint: Baseline, the end of the study. Method of measurement: Secretion, Edema, Erythema And Desquamation. | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c. Timepoint: Baseline, the end of the study. Method of measurement: Laboratory blood test.;Urea. Timepoint: Baseline, the end of the study. Method of measurement: Laboratory blood test.;2Hpp. Timepoint: Baseline, the end of the study. Method of measurement: Laboratory blood test.;CBC. Timepoint: Baseline, the end of the study. Method of measurement: Laboratory blood test.;FBS. Timepoint: Baseline, the end of the study. Method of measurement: Laboratory blood test.;Blood pressure. Timepoint: Baseline, the end of the study. Method of measurement: Manometer.;Creatinine. Timepoint: Baseline, the end of the study. Method of measurement: Laboratory blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactYones Najafian Razavi
Faculty of Iranian Traditional Medicine and Complementary of Mashhad University of Medical Sciences
Outcome results
None listed